- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Frequency of Serious Adverse Skin Reactions Caused by Continuous Subcutaneous Administration of Psychotropic Drugs
-
- Yabuki Ritsuko
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Hisanaga Takayuki
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Kiuchi Daisuke
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Shimokawa Miho
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Abe Katsuya
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Otsuka Takahiro
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
-
- Sakurai Ayako
- Department of Nursing, ditto
-
- Suda Satoko
- Department of Nursing, ditto
-
- Shima Yasuo
- Department of Palliative Medicine, Tsukuba Medical Center Hospital
Bibliographic Information
- Other Title
-
- 向精神薬の持続皮下投与における重篤な皮膚有害事象の発生頻度の検討
Search this article
Description
Continuous subcutaneous injections of medication are effective in controlling symptoms of the terminal stage of cancer. Chlorpromazine and levomepromazine occasionally cause skin irritation. We examined all patients who underwent continuous subcutaneous administration of psychotropic drugs (chlorpromazine, levomepromazine, midazolam) at the palliative care unit of our hospital from April 2010 to March 2013, the frequency of adverse skin reactions of Common Terminology Criteria for Adverse Events (CTCAE) v4.0 grade 3 or above. Of the 603 hospitalized patients, 389 (64.5%) underwent continuous subcutaneous administration of one of the three drugs. The frequency of grade 3 or above (ulceration or necrosis) adverse skin reactions was 4 out of 345 chlorpromazine cases (1.2%; 95% CI: 0.0-2.3%), 2 out of 90 levomepromazine cases (2.2%; 95% CI: −0.8-5.2%), and 0 out of 210 midazolam cases (0.0%; 95% CI: 0.0-0.0%). The frequency of serious adverse skin reactions caused by continuous subcutaneous administration of psychotropic drugs was low, suggesting that this treatment is relatively safe for the skin.
Journal
-
- Palliative Care Research
-
Palliative Care Research 11 (1), 123-127, 2016
Japanese Society for Palliative Medicine
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390282680234804992
-
- NII Article ID
- 130005128610
-
- ISSN
- 18805302
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed